JP5117374B2 - Ｃｈｋ１阻害に有用なヘテロアリール尿素誘導体 - Google Patents

Ｃｈｋ１阻害に有用なヘテロアリール尿素誘導体 Download PDF

Info

Publication number
JP5117374B2
JP5117374B2 JP2008504337A JP2008504337A JP5117374B2 JP 5117374 B2 JP5117374 B2 JP 5117374B2 JP 2008504337 A JP2008504337 A JP 2008504337A JP 2008504337 A JP2008504337 A JP 2008504337A JP 5117374 B2 JP5117374 B2 JP 5117374B2
Authority
JP
Japan
Prior art keywords
compound
methyl
chk1
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008504337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535830A (ja
JP2008535830A5 (cg-RX-API-DMAC7.html
Inventor
フランク・ディアス
フランシーヌ・エス・ファルーズ
ライアン・シー・ホルクーム
エドワード・エイ・ケシッキ
フア・チー・ウーイ
アレキサンダー・ルドルフ
フランク・スタッペンベック
ユージーン・ディ・ソーセット
ジョン・ジョゼフ・ガウディーノ
キンバ・エル・フィッシャー
アダム・ウェイド・クック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icos Corp
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Publication of JP2008535830A publication Critical patent/JP2008535830A/ja
Publication of JP2008535830A5 publication Critical patent/JP2008535830A5/ja
Application granted granted Critical
Publication of JP5117374B2 publication Critical patent/JP5117374B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
JP2008504337A 2005-03-29 2006-03-29 Ｃｈｋ１阻害に有用なヘテロアリール尿素誘導体 Expired - Fee Related JP5117374B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66602605P 2005-03-29 2005-03-29
US60/666,026 2005-03-29
PCT/US2006/011584 WO2006105262A1 (en) 2005-03-29 2006-03-29 HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009122107A Division JP2009227682A (ja) 2005-03-29 2009-05-20 Ｃｈｋ１阻害に有用なヘテロアリール尿素誘導体

Publications (3)

Publication Number Publication Date
JP2008535830A JP2008535830A (ja) 2008-09-04
JP2008535830A5 JP2008535830A5 (cg-RX-API-DMAC7.html) 2009-07-09
JP5117374B2 true JP5117374B2 (ja) 2013-01-16

Family

ID=36677174

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008504337A Expired - Fee Related JP5117374B2 (ja) 2005-03-29 2006-03-29 Ｃｈｋ１阻害に有用なヘテロアリール尿素誘導体
JP2009122107A Pending JP2009227682A (ja) 2005-03-29 2009-05-20 Ｃｈｋ１阻害に有用なヘテロアリール尿素誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009122107A Pending JP2009227682A (ja) 2005-03-29 2009-05-20 Ｃｈｋ１阻害に有用なヘテロアリール尿素誘導体

Country Status (31)

Country Link
US (1) US8093244B2 (cg-RX-API-DMAC7.html)
EP (2) EP1869020B1 (cg-RX-API-DMAC7.html)
JP (2) JP5117374B2 (cg-RX-API-DMAC7.html)
KR (2) KR100912998B1 (cg-RX-API-DMAC7.html)
CN (2) CN102219784A (cg-RX-API-DMAC7.html)
AR (1) AR056645A1 (cg-RX-API-DMAC7.html)
AT (1) ATE490248T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006230337B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0609667A2 (cg-RX-API-DMAC7.html)
CA (1) CA2602199C (cg-RX-API-DMAC7.html)
CR (1) CR9395A (cg-RX-API-DMAC7.html)
CY (1) CY1111240T1 (cg-RX-API-DMAC7.html)
DE (1) DE602006018590D1 (cg-RX-API-DMAC7.html)
DK (1) DK1869020T3 (cg-RX-API-DMAC7.html)
EA (1) EA011287B1 (cg-RX-API-DMAC7.html)
ES (1) ES2356068T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20100678T1 (cg-RX-API-DMAC7.html)
IL (1) IL185481A0 (cg-RX-API-DMAC7.html)
MA (1) MA29439B1 (cg-RX-API-DMAC7.html)
MX (1) MX2007012116A (cg-RX-API-DMAC7.html)
NO (1) NO20074944L (cg-RX-API-DMAC7.html)
NZ (1) NZ561458A (cg-RX-API-DMAC7.html)
PL (1) PL1869020T3 (cg-RX-API-DMAC7.html)
PT (1) PT1869020E (cg-RX-API-DMAC7.html)
RS (1) RS51616B (cg-RX-API-DMAC7.html)
SI (1) SI1869020T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN07369A1 (cg-RX-API-DMAC7.html)
TW (1) TWI375559B (cg-RX-API-DMAC7.html)
UA (1) UA92164C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006105262A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200707715B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH062640B2 (ja) 1988-08-03 1994-01-12 インターナシヨナル・ビジネス・マシーンズ・コーポレーシヨン 単結晶ヘテロ構造及びその形成方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ575394A (en) 2006-10-20 2012-01-12 Icos Corp Compositions of chk1 inhibitors and cyclodextrin
CN101200429B (zh) * 2006-12-13 2012-08-22 上海睿智化学研究有限公司 2-硝基-4,5-二卤代苯酚类和2-氨基-4,5-二卤代苯酚类及其盐及其合成方法
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
CA3013514C (en) 2016-02-04 2021-11-23 Pharmaengine, Inc. 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
KR20190130621A (ko) * 2017-03-31 2019-11-22 시애틀 지네틱스, 인크. Chk1 저해제와 wee1 저해제의 조합물
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
US12404332B2 (en) * 2020-03-13 2025-09-02 Research Development Foundation Methods for diagnosing and treating cancers
NL2039212B1 (en) 2024-12-02 2026-06-23 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Mitotic cell phase enrichment and ionizing radiation

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293552A (en) 1978-02-27 1981-10-06 Eli Lilly And Company Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
US6174993B1 (en) 1997-05-21 2001-01-16 The Children's Medical Center Corp. Short peptides which selectively modulate the activity of serine/threonine kinases
US6218109B1 (en) 1997-09-05 2001-04-17 Baylor College Of Medicine Mammalian checkpoint genes and proteins
GB9718952D0 (en) 1997-09-05 1997-11-12 Medical Res Council Mammalian chk1 effector cell cycle checkpoint protein kinase materials and methods
DE69818083T2 (de) 1997-10-06 2004-07-08 Abbott Gmbh & Co. Kg INDENO[1,2-c]-,NAPHTHO[1,2-C]-UND BENZO[6,7]CYCLOHEPTA[1,2-c]PYRAZOLDERIVATE
EP1135135A4 (en) 1998-09-18 2006-08-09 Smithkline Beecham Corp CHK1 KINASE INHIBITORS
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
WO2001057206A2 (en) 2000-02-03 2001-08-09 Ribozyme Pharmaceuticals, Inc. Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme
WO2001062900A1 (en) 2000-02-25 2001-08-30 The Regents Of The University Of California. Scytonemin and methods of using thereof
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
US6534691B2 (en) 2000-07-18 2003-03-18 E. I. Du Pont De Nemours And Company Manufacturing process for α-olefins
MXPA03001452A (es) 2000-08-18 2004-05-04 Agouron Pharma Hidroximino-fluorenos heterociclicos y su uso para la inhibicion de las proteinas cinasas.
US20040116497A1 (en) 2001-01-26 2004-06-17 Gabriella Traquandi Chromane derivatives, process for their preparation and their use as antitumor agents
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
JP2004536113A (ja) 2001-07-03 2004-12-02 カイロン コーポレイション チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003029241A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
US7166639B2 (en) 2001-10-04 2007-01-23 Smithkline Beecham Corporation NF-κB inhibitors
WO2003028731A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
AU2002356871A1 (en) 2001-10-30 2003-05-12 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US20030119839A1 (en) 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
AU2003224341A1 (en) 2002-04-26 2003-11-10 Warner-Lambert Company Llc Inhibitors of checkpoint kinases (wee1 and chk1)
AU2003243318A1 (en) * 2002-05-29 2003-12-19 Millennium Pharmaceuticals, Inc. Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
US20040034038A1 (en) 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
US7056925B2 (en) * 2002-08-13 2006-06-06 Abbott Laboratories Urea kinase inhibitors
EP2573079A3 (en) 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
WO2004048343A1 (en) 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
EA009337B1 (ru) 2003-01-09 2007-12-28 Пфайзер Инк. Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии
AU2005267185A1 (en) * 2004-06-25 2006-02-02 Icos Corporation Bisarylurea derivatives useful for inhibiting CHK1
CA2679908A1 (en) 2009-09-23 2011-03-23 Shell Internationale Research Maatschappij B.V. Closed loop solvent extraction process for oil sands
CN104407475B (zh) 2014-12-04 2017-04-05 厦门天马微电子有限公司 液晶显示面板

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH062640B2 (ja) 1988-08-03 1994-01-12 インターナシヨナル・ビジネス・マシーンズ・コーポレーシヨン 単結晶ヘテロ構造及びその形成方法

Also Published As

Publication number Publication date
PT1869020E (pt) 2010-12-23
ES2356068T3 (es) 2011-04-04
ZA200707715B (en) 2009-09-30
JP2009227682A (ja) 2009-10-08
WO2006105262A1 (en) 2006-10-05
MX2007012116A (es) 2008-04-08
CY1111240T1 (el) 2015-06-11
TWI375559B (en) 2012-11-01
US8093244B2 (en) 2012-01-10
DK1869020T3 (da) 2011-01-24
UA92164C2 (ru) 2010-10-11
TW200722090A (en) 2007-06-16
CN101151259B (zh) 2011-06-15
NZ561458A (en) 2011-03-31
AU2006230337B2 (en) 2011-10-27
HK1119670A1 (en) 2009-03-13
JP2008535830A (ja) 2008-09-04
BRPI0609667A2 (pt) 2010-04-20
TNSN07369A1 (en) 2008-12-31
CR9395A (es) 2008-03-31
EA200702094A1 (ru) 2008-02-28
EA011287B1 (ru) 2009-02-27
KR20090031459A (ko) 2009-03-25
RS51616B (sr) 2011-08-31
CN102219784A (zh) 2011-10-19
KR20070107178A (ko) 2007-11-06
CA2602199A1 (en) 2006-10-05
US20090143357A1 (en) 2009-06-04
DE602006018590D1 (de) 2011-01-13
EP1869020B1 (en) 2010-12-01
CN101151259A (zh) 2008-03-26
EP1869020A1 (en) 2007-12-26
NO20074944L (no) 2007-10-24
HRP20100678T1 (hr) 2011-02-28
KR100912998B1 (ko) 2009-08-20
IL185481A0 (en) 2008-01-06
ATE490248T1 (de) 2010-12-15
AU2006230337A1 (en) 2006-10-05
AR056645A1 (es) 2007-10-17
PL1869020T3 (pl) 2011-05-31
MA29439B1 (fr) 2008-05-02
EP2330105A1 (en) 2011-06-08
CA2602199C (en) 2013-09-10
SI1869020T1 (sl) 2011-02-28

Similar Documents

Publication Publication Date Title
JP2009227682A (ja) Ｃｈｋ１阻害に有用なヘテロアリール尿素誘導体
US7560462B2 (en) Compounds useful for inhibiting CHK1
JP2008535830A5 (cg-RX-API-DMAC7.html)
US20080318974A1 (en) Compounds Useful for Inhibiting Chk1
KR101457027B1 (ko) 트리아진 유도체와 이들의 치료적 용도
CN101006075A (zh) 可用于抑制chk1的双芳基脲衍生物
HK1119670B (en) Heteroaryl urea derivatives useful for inhibiting chk1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120821

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121002

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121017

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151026

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees